Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
A Phase II Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Locally Advanced HER2-positive Breast Cancer
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
Difficulty in completing enrollment within the planned time
Other terminated trials from Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Advanced Solid Tumor · Phase PHASE1/PHASE2 · Jul 2025
- Colorectal Cancer with Hepatic Metastases · Phase PHASE2 · Jan 2025
- Advanced Solid Tumor · Phase PHASE1 · Nov 2023
- Thymic Carcinoma · Phase PHASE2 · Jul 2023
- Thymic Carcinoma · Phase PHASE2 · May 2023
More terminations from Jiangsu Alphamab Biopharmaceuticals Co., Ltd
This observational or N/A phase trial investigates HER2-positive Metastatic Breast Cancer and is currently terminated or withdrawn. Jiangsu Alphamab Biopharmaceuticals Co., Ltd leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Aug 2023 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Jul 2022 — Aug 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Jul 2022 [monthly]
Not Yet Recruiting
▶ Show 1 earlier version
-
Apr 2021 — Dec 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .